|1.||Urasaki, Y: 2 articles (09/2001 - 05/2001)|
|2.||Kishi, S: 2 articles (09/2001 - 05/2001)|
|3.||Ueda, T: 2 articles (09/2001 - 05/2001)|
|4.||Yamauchi, T: 2 articles (09/2001 - 05/2001)|
|5.||Kawai, Y: 2 articles (09/2001 - 05/2001)|
|6.||Imamura, S: 2 articles (09/2001 - 05/2001)|
|7.||Yoshida, A: 2 articles (09/2001 - 05/2001)|
|8.||Goto, N: 2 articles (09/2001 - 05/2001)|
|9.||Iwasaki, H: 2 articles (09/2001 - 05/2001)|
|10.||Masada, M: 2 articles (09/2001 - 05/2001)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/1980 - "One patient with acute myeloblastic leukemia achieved complete remission with 5.0 mg/kg BH-AC given daily for 21 days. "
09/01/2001 - "Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia."
06/01/1988 - "[Pharmacokinetic studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) by 30-minute infusion with acute nonlymphocytic leukemia--the possibility of administration for outpatients]."
09/01/1983 - "[Clinical studies of BH-AC-DMP in adult acute nonlymphocytic leukemia]."
02/01/1999 - "Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenous leukemia."
01/01/1980 - "It pharmacologic features, minimal toxicity, and the capability of inducing complete remission in acute leukemia indicate that BH-AC undoubtedly deserves further prospective clinical trials."
04/01/1988 - "The results suggest that administration of intermediate and high doses of BH-AC, accompanied by HDC, will prove a safe, effective means of enhancing the efficacy of leukemia therapy."
09/01/2001 - "N(4)-Behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC), a prodrug of 1-beta-D-arabinofuranosylcytosine, is used effectively for the treatment of leukemia in Japan. "
12/01/1980 - "Phase III study of N4-behenoyl-l-beta-D-arabinofuranosylcytosine in adult acute leukemia-BH-AC-DMP therapy."
01/01/1980 - "Initial phase I study of BH-AC was evaluated in 14 patients with leukemia and other malignancies. "
09/01/1986 - "BH-AC group) for 64 patients with a variety of solid cancers. "
09/01/1986 - "This study suggests that combined chemotherapy of MF plus BH-AC is more effective on a variety of solid cancers in comparison to MF therapy."
01/01/1989 - "Our findings show that ara-C and BH-AC are equally cytostatic to human tumors. "
12/01/1994 - "He was diagnosed as having a chronic myeloproliferative disorder with tumor formation and was treated with anti-leukemia drugs, including BH-AC, THP, VDS, MTX, VP-16, BUS, 6MP and uvenimex. "
01/01/1983 - "These groups were treated with the protocol (DCMP two step, BH-AC DMP, BH-AC AMP) established by the Yamada Leukemia Study Group of the Japan Welfare Ministry Cancer Research Project (chairman Yamada, K). "
06/01/1992 - "[BH-AC.nitrosourea-therapy for refractory or relapsed malignant lymphoma]."
11/01/1991 - "These results supported the evidence that combination of BH-AC with MCNU was effective in patients with multi-drug resistant malignant lymphomas."
03/01/1982 - "[Treatment of malignant lymphoma with single administration of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosylcytosine]."
04/01/1992 - "Forty one patients with refractory malignant lymphoma were treated with a combination of VP-16, ACM, BH-AC, MTX and PDN as a salvage chemotherapy. "
01/01/1989 - "The mean of the SD activity at 88 microM was 65.7 +/- 11.5% for ara-C and 61.4 +/- 14.5% for BH-AC in gastrointestinal cancers, and 63.8 +/- 16.0% for ara-C and 58.3 +/- 18.3% for BH-AC in malignant lymphomas with a statistically significant difference (p less than 0.05). "
10/01/1983 - "[Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia]."
11/01/1984 - "[Acute pancreatitis during the treatment of BH-AC AMP regimen for acute non-lymphocytic leukemia]."
06/01/1983 - "Eight adults with acute non-lymphocytic leukemia refractory to BH-AC.DMP therapy (N4-behenoyl-1-beta-D-arabinofuranosylcytosine, daunomycin, 6-mercaptopurine and prednisolone) were treated with a combination therapy of anthracycline antibiotics: adriamycin and aclacinomycin A (AA therapy). "
01/20/1990 - "A 55-year-old male with acute non-lymphocytic leukemia (M2) achieved complete remission by combination chemotherapy of Behenoyl-ara-C, Daunorubicin, 6-Mercaptopurine and Prednisolone in July, 1985. "
|5.||Etoposide (VP 16)
|7.||Adenosine Monophosphate (AMP)
|10.||Deoxycytidine Monophosphate (DCMP)
|1.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Drug Therapy (Chemotherapy)